Floatz logo

Recombinant Human EGF-rP64K

Stage III Lung Cancer AJCC v8

Roswell Park Cancer InstitutePhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

303 Active assets in the Stage III Lung Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
University of Vermont
Phase 4BB
Carboplatin
SystImmune Inc.
Phase 4BB
Nivolumab
University of Chicago
Phase 4BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB

View all 50 →

Same molecule, other indications

Recombinant Human EGF-rP64K is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
head and neck squamous cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
skin squamous cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →